000126017 001__ 126017
000126017 005__ 20240228140802.0
000126017 0247_ $$2doi$$a10.1007/s00259-014-2949-6
000126017 0247_ $$2pmid$$apmid:25411132
000126017 0247_ $$2pmc$$apmc:PMC4315487
000126017 0247_ $$2ISSN$$a0340-6997
000126017 0247_ $$2ISSN$$a1432-105X
000126017 0247_ $$2ISSN$$a1619-7070
000126017 0247_ $$2ISSN$$a1619-7089
000126017 0247_ $$2altmetric$$aaltmetric:2912988
000126017 037__ $$aDKFZ-2017-02132
000126017 041__ $$aeng
000126017 082__ $$a610
000126017 1001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b0$$eFirst author$$udkfz
000126017 245__ $$aThe diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
000126017 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2015
000126017 3367_ $$2DRIVER$$aarticle
000126017 3367_ $$2DataCite$$aOutput Types/Journal article
000126017 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522138308_18537
000126017 3367_ $$2BibTeX$$aARTICLE
000126017 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126017 3367_ $$00$$2EndNote$$aJournal Article
000126017 520__ $$aSince the introduction of positron emission tomography (PET) imaging with (68)Ga-PSMA-HBED-CC (=(68)Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim of this evaluation was to analyse the diagnostic value of (68)Ga-PSMA-ligand PET/CT in a large cohort and the influence of several possibly interacting variables.We performed a retrospective analysis in 319 patients who underwent (68)Ga-PSMA-ligand PET/CT from 2011 to 2014. Potential influences of several factors such as prostate-specific antigen (PSA) level and doubling time (DT), Gleason score (GSC), androgen deprivation therapy (ADT), age and amount of injected tracer were evaluated. Histological verification was performed in 42 patients after the (68)Ga-PSMA-ligand PET/CT. Tracer uptake was measured in 901 representative tumour lesions.In 82.8% of the patients at least one lesion indicative of PCa was detected. Tumor-detection was positively associated with PSA level and ADT. GSC and PSA-DT were not associated with tumor-detection. The average maximum standardized uptake value (SUVmax) of tumour lesions was 13.3 ± 14.6 (0.7-122.5). Amongst lesions investigated by histology, 30 were false-negative in 4 different patients, and all other lesions (n = 416) were true-positive or true-negative. A lesion-based analysis of sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) revealed values of 76.6%, 100%, 91.4% and 100%. A patient-based analysis revealed a sensitivity of 88.1%. Of 116 patients available for follow-up, 50 received local therapy after (68)Ga-PSMA-ligand PET/CT.(68)Ga-PSMA-ligand PET/CT can detect recurrent PCa in a high number of patients. In addition, the radiotracer is highly specific for PCa. Tumour detection is positively associated with PSA and ADT. (68)Ga-PSMA-ligand PET/CT can help delay systemic therapy of PCa.
000126017 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126017 588__ $$aDataset connected to CrossRef, PubMed,
000126017 650_7 $$2NLM Chemicals$$aGlu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
000126017 650_7 $$2NLM Chemicals$$aOligopeptides
000126017 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000126017 650_7 $$09G34HU7RV0$$2NLM Chemicals$$aEdetic Acid
000126017 7001_ $$0P:(DE-HGF)0$$aAvtzi, Eleni$$b1
000126017 7001_ $$0P:(DE-HGF)0$$aGiesel, Frederik L$$b2
000126017 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b3$$udkfz
000126017 7001_ $$0P:(DE-HGF)0$$aLinhart, Heinz G$$b4
000126017 7001_ $$0P:(DE-He78)331382460d902d1341dc73db8b990f97$$aEder, Matthias$$b5$$udkfz
000126017 7001_ $$0P:(DE-HGF)0$$aEisenhut, Michael$$b6
000126017 7001_ $$aBoxler, Silvan$$b7
000126017 7001_ $$aHadaschik, Boris A$$b8
000126017 7001_ $$0P:(DE-HGF)0$$aKratochwil, Clemens$$b9
000126017 7001_ $$aWeichert, Wilko$$b10
000126017 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b11$$udkfz
000126017 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b12$$udkfz
000126017 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b13$$eLast author$$udkfz
000126017 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-014-2949-6$$gVol. 42, no. 2, p. 197 - 209$$n2$$p197 - 209$$tEuropean journal of nuclear medicine and molecular imaging$$v42$$x1619-7089$$y2015
000126017 909CO $$ooai:inrepo02.dkfz.de:126017$$pVDB
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)331382460d902d1341dc73db8b990f97$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000126017 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000126017 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126017 9141_ $$y2015
000126017 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126017 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126017 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126017 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126017 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126017 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000126017 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126017 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126017 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126017 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126017 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126017 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126017 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000126017 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000126017 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000126017 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x2
000126017 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x3
000126017 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x4
000126017 980__ $$ajournal
000126017 980__ $$aVDB
000126017 980__ $$aI:(DE-He78)E060-20160331
000126017 980__ $$aI:(DE-He78)C060-20160331
000126017 980__ $$aI:(DE-He78)G010-20160331
000126017 980__ $$aI:(DE-He78)E030-20160331
000126017 980__ $$aI:(DE-He78)E050-20160331
000126017 980__ $$aUNRESTRICTED